Introduction
'Ecstasy', 3,4-methylenedioxymethamphetamine (MDMA), is an amphetamine-like substance which is used as a recreational drug due to its euphoric and stimulant effects. Its popularity in the past forty years has significantly increased, particularly in the USA and UK, 1 and an increasing number of overdoserelated fatalities are reported with its use. 2 MDMA acts as an indirect mono-aminergic agonist and its physical and psychological effects have been mostly attributed to altered neuronal serotonin homeostasis. 3, 4 MDMA has strong affinity for neuronal serotonin receptors, causing serotonin release into the extracellular space, its metabolism and resulting depletion. Dopamine and noradrenaline release has also been recognised as an important mechanism underlying the stimulant properties of the drug.
Physical features of the acute response include hyperthermia, tachycardia, hypertension, tremor, abnormal movements, restlessness, and pupillary dilatation. Psychological effects include euphoria, increased energy and a subjective 'closeness' to others. 5, 6 Effects become evident from around 20 minutes following oral ingestion and last three to four hours. 7 Residual features such as confusion, depression and anxiety may rarely persist for several days to weeks. The mechanism for its long-term effects, which include shortterm memory and cognitive impairment is unclear, but may involve irreversible axonal damage, particularly to serotonergic neurones. 8 Treatment of acute toxicity requires monitoring for several hours in a calm environment until symptoms resolve. For patients with severe toxicity however, management focuses on the correction of the adverse effects, particularly hyperthermia and hypertension.
Lysergic acid diethylamide (LSD) or 'acid' is a synthetic hallucinogen which was originally used in the 1950s as an experimental psychiatric drug. 9 It is absorbed rapidly following oral ingestion, with effects manifesting within thirty minutes and lasting eight to ten hours. 10 It acts as a partial agonist at the serotonin receptor 11 causing alterations in thought, mood and perception. Physical effects are similar to MDMA, with sympathomimetic features dominant. Treatment principles are also similar to MDMA toxicity.
We present a case of a young man who presented with coma. Urine and blood toxicology were negative. Neuroimaging suggested toxic substance abuse, subsequently confirmed by collateral history.
Case presentation
A previously fit and well 22-year-old Caucasian man was admitted to intensive care from the emergency department. He had been unconscious (GCS 3/15) for approximately 24 hours. Respiratory rate was 36 breaths/min, heart rate 120/min, blood pressure 125/65 mm Hg, and he was pyrexial, 38.2°C. Blood glucose was normal. There was no external evidence of trauma. He was intubated, mechanically ventilated, sedated, and transferred to the intensive care unit for further management. History revealed that prior to admission, the patient had consumed alcohol and possibly illicit drugs and he subsequently had a short history of diarrhoea and vomiting.
Bloods on admission demonstrated rhabdomyolysis (CK 8,468 u/L) and deranged liver function tests (ALT 6,522 u/L,
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ALP 131 u/L, GGT 65 u/L, INR 1.6, albumin 44 g/L). White cell count was 28.0×10 9 /L with neutrophilia (25.7×10 9 /L). Acid-base status demonstrated a respiratory alkalosis (pH 7.56, pCO 2 3.47 kPa, HCO 3 -26.0 mmoL/L, pO 2 10.70 kPa) with a mildly raised lactate level (3.7 mmol/L). Blood and urine toxicology were negative for paracetamol, opiates, benzodiazepines, amphetamines and MDMA. Cranial CT was normal. A lumbar puncture was performed, and ceftriaxone and acyclovir started to treat possible intracranial infection.
Despite the rhabdomyolysis, he maintained good urine output with fluid resuscitation followed by strict fluid balance. Paracetamol was administered for his intermittent periods of pyrexia and there was clinical improvement with supportive care, with laboratory evidence of normalising inflammatory markers, creatinine kinase and liver function. Despite this he continued to have episodes of severe systolic hypertension (systolic BP 170-180 mm Hg) and agitation. CSF analysis, including meningococcal and pneumococcal, N. meningitides nucleic acid, and Strep. pneumonia nucleic acid was normal, so ceftriaxone was stopped. Further infection screens including blood, urine and sputum cultures, HIV, and hepatitis screens were also negative. An electroencephalogram demonstrated nonspecific findings consistent with diffuse cerebral dysfunction.
By the fifth day in intensive care, he had improved, was extubated and discharged to ward care. CSF viral serology was reported to be negative and acyclovir was subsequently stopped.
During the patient' s recovery on the ward, neurological examination revealed persisting abnormal neurological signs with neck stiffness, generalised hyper-reflexia, right upgoing plantar response, and right lower limb weakness (MRC grade 2/5). His pupils were dilated and sluggishly responsive to light and accommodation. The neurological findings were initially attributed to hypoxic brain injury. However, an MRI of the brain revealed unusual punctate haemorrhages and hyperintensities throughout the supraventricular white matter, periventricular white matter, cerebellum, brainstem and corpus callosum, as well as restricted diffusion (Figures 1-3) . These features were not consistent with a purely hypoxic or inflammatory injury. Neuroradiology opinion confirmed these were consistent with toxic encephalitis, most likely secondary to psychoactive drugs, and further clarification of the history was sought. This confirmed ingestion of both MDMA and LSD, and a prior history of illicit drug use. The patient was reviewed six months after initial presentation. His symptoms had resolved and his neurological state was normal.
Discussion
This patient' s presenting features were consistent with severe toxicity from MDMA and LSD ingestion. The environment in which the patient ingested the drugs could not be established from the history, but this may have played a role in the development of toxicity, as there is evidence that the hyperthermia associated with MDMA ingestion is dependent on environmental temperature, with increased risk of toxicity the warmer the ambient temperature. 2 The association between hyperthermia and rhabdomyolysis is well reported and in relation to amphetamine toxicity, usually results from excessive muscle activity at social gatherings coupled with poor fluid replacement. However for our patient, the 24-hour history of coma also played a key role. In patients with hyperthermia and rhabdomyolysis, multi-organ dysfunction can rapidly ensue. Hepatic dysfunction secondary to MDMA has also been reported and may range from a self-resolving acute hepatitis to fulminant hepatic failure. 12, 13 The liver impairment observed in this case was initially attributed to acute liver ischaemia, however it is difficult to determine whether the direct effects of MDMA also contributed. Hyponatraemia due to release of anti-diuretic hormone, is another adverse complication 14, 15 which was not observed in this case. Intracerebral haemorrhages, attributed to the acute changes in blood pressure, 16 have also been reported with MDMA toxicity and may explain the episodes of hypertension our patient experienced in intensive care, as well as the punctate haemorrhages observed on neuro-imaging.
Case reports
The quantity of each drug ingested could not be established. The relationship between MDMA ingestion and blood concentration does not follow linear kinetics and therefore toxicity is always a risk. 7 In addition, genetic mutations in metabolising hepatic enzymes may result in a greater toxicity risk in 'slow metabolisers.' 17 Thus one should have a low threshold for suspicion of toxicity regardless of the dose ingested. The purity of 'ecstasy' tablets is also important, as MDMA content may vary significantly from tablet to tablet and may include other illicit or psychoactive substances such as 3,4-methylenedioxyamphetamine (MDA) or 3,4-methylenedioxyethylamphetamine (MDE). Latest figures, however, report that MDMA content in 'ecstasy' tablets is between 90-100%, much higher than reported figures in the late 20th century. 18 Another important part of the history that could not be established accurately was the duration between ingestion and presentation. Urine toxicology screening for amphetamines has a low sensitivity for MDMA and therefore, if MDMA ingestion is suspected, specific tests involving monoclonal antibodies 19 are required, which were used in this case. Specific MDMA urine detection is possible within a 24-72 hour window from ingestion with 50-100 mg. Blood screening involves the detection of both MDMA and its metabolites, with the window of detection slightly shorter at 24 hours. 20 LSD is excreted in the urine mostly in the form of an inactive metabolite with only a small amount excreted as LSD. 21 Urine detection is possible with advanced radioimmunoassay for 24-48 hours following ingestion, 22 however due to the advanced methods required this is rarely performed, as in the present case.
An association between MDMA use and toxic leukoencephalopathy has been reported 23 and is most readily confirmed with a combination of clinical and radiological features. Toxic leukoencephalopathy describes a wide spectrum of neurological deficits which are secondary to structural damage of white matter in the cerebrum, including myelin, oligodendrocytes, and axons. 24 Aetiology includes a wide variety of insults such as irradiation, environmental toxins, chemotherapy, immunosuppressive therapy and illicit drugs including heroin and MDMA. The prevalence of this condition is unknown but with the increasing availability of MRI scanning and better care of patients who have been exposed to such leukotoxic agents, an increasing number of cases is being reported. After MDMA ingestion, leukoencephalopathy is believed to be due to serotonergic neuronal damage and possibly damage to myelin from oxidative stress. 8, 25 To our knowledge there are no case reports of LSD toxicity causing such neuro-radiological changes; however due to similar modes of action, the contribution of LSD, as well as other illicit drug use, cannot be excluded. As pathology is mostly limited to the white matter, clinical features range from confusion, amnesia and personality changes to stupor, white matter dementia, coma and even death in severe cases. Radiological findings include hyperintensity of supraventricular and periventricular white matter in mild cases, as in our patient, to severe hyperintensity of white matter and necrosis in the most severe of cases, 24 with features most prominent on diffusionweighted imaging. 26 Although reversibility is the norm for the majority of mild cases, irreversible changes have been reported, particularly with anti-neoplastic toxins. 27, 28 As treatment options are fairly limited, early recognition and withdrawal of the offending agent are of the upmost importance.
Conclusion
Substance abuse is a growing concern in the western world with the number of presentations to the emergency department increasing, and there should be a high index of suspicion in patients who fit the clinical picture of drug toxicity. Treatment for MDMA and LSD toxicity usually only requires supportive measures; however there should be a low threshold for suspecting complications of severe toxicity regardless of the dose ingested. One should also be aware of the limitations with regards to toxicology screening and the limited time frame required for detection.
Toxic leukoencephalopathy is an important complication of MDMA toxicity and can present with a spectrum of neurological findings, particularly neuro-behavioural disorders, and may be the only clinical evidence of substance abuse. Diagnosis can be made with a combination of clinical findings Case reports Figure 3 Axial T2 diffusion-weighted MRI of the brain demonstrating restricted diffusion. and neuro-imaging. Physicians must be aware of this association as early recognition and withdrawal of the causative agent can prevent irreversible cerebral damage, long-term morbidity and even fatality. And finally, the value of the collateral history in reaching a diagnosis and determining aetiology should never be underestimated.
